Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18434324
Lomonaco SL, et al. (2008) Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide. J Biol Chem 283, 17731-9 18434324
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y64-p - PKCD (human)
Modsite: STFDAHIyEGRVIQI SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y64‑p, PKCD iso2 (human): Y64‑p, PKCD (mouse): Y64‑p, PKCD iso2 (mouse): Y64‑p, PKCD (rat): Y64‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, induced
Comments:  ERK phosphorylation/activation

Y187-p - PKCD (human)
Modsite: WGLNkQGyKCRQCNA SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y187‑p, PKCD iso2 (human): Y187‑p, PKCD (mouse): Y187‑p, PKCD iso2 (mouse): Y187‑p, PKCD (rat): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, induced
Comments:  ERK phosphorylation/activation

T183-p - JNK2 (mouse)
Modsite: ACTNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

Y185-p - JNK2 (mouse)
Modsite: TNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
siRNA etoposide PKCD (rat) inhibit treatment-induced increase
etoposide PKCD (human) inhibit treatment-induced increase dominant negative
TRAIL increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
siRNA etoposide PKCD (rat) inhibit treatment-induced increase
etoposide PKCD (human) inhibit treatment-induced increase dominant negative
TRAIL increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
siRNA etoposide PKCD (rat) inhibit treatment-induced increase
etoposide PKCD (human) inhibit treatment-induced increase dominant negative
TRAIL increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase
siRNA etoposide PKCD (rat) inhibit treatment-induced increase
etoposide PKCD (human) inhibit treatment-induced increase dominant negative
TRAIL increase

T219-p - ERK5 (rat)
Modsite: AEHQYFMtEyVATRW SwissProt Entrez-Gene
Orthologous residues
ERK5 (human): T219‑p, ERK5 iso2 (human): T80‑p, ERK5 (mouse): T219‑p, ERK5 (rat): T219‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

Y221-p - ERK5 (rat)
Modsite: HQYFMtEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK5 (human): Y221‑p, ERK5 iso2 (human): Y82‑p, ERK5 (mouse): Y221‑p, ERK5 (rat): Y221‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

T183-p - JNK1 (rat)
Modsite: AGTsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

Y185-p - JNK1 (rat)
Modsite: TsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

T180-p - P38A (rat)
Modsite: RHTDDEMtGyVATRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase

Y182-p - P38A (rat)
Modsite: TDDEMtGyVATRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioma
Relevant cell lines - cell types - tissues:  C6 (glial)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
etoposide increase